In this episode, Hall welcomes Gary Madsen of ProTransit Nanotherapy. Gary Madsen, Ph.D., has over 30 years of experience in developing and launching biotechnology products in a wide variety of markets at companies of various sizes. He spent 17 years at Abbott Laboratories in product support, new product development and business development. His expertise in product commercialization has helped him to success building new technologies; today that has led him to a promising new technology — nanoparticle drug delivery.
Gary advises that potential investors in biotechnology make sure that the technology is workable, scalable, and that it has good supporting data beyond just slick advertising. Gary explains some of the technology behind nanoparticle drug delivery, and its potential applications. In addition, Gary touches on why skincare is a good entry point for new technology, as well as some of the technical challenges in scaling production. Finally, Gary outlines some of things that ProTransit has done to set themselves up for success as they pursue additional applications for their technology.
You can find ProTransit Nanotherapy at https://protransitnanotherapy.com
Gary can be reached on LinkedIn at linkedin.com/in/gary-madsen-bb9254
Copyright (c) 2020, Hall Martin and investorconnect.org. All rights reserved.
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.